Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Bitdeer Technologies Group (BTDR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Bitdeer Technologies Group — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Bitdeer Technologies Group trades at $12.5 (market cap $3.01B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.7× Bitdeer Technologies Group's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.
| BIO | BTDR | |
|---|---|---|
Market Cap | $8.04B | $3.01B |
Sector | Health | Technology |
52-Week High | $339.75 | $25.90 |
52-Week Low | $241.71 | $7.28 |
Enterprise Value | $7.85B | $4.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
BTDR trades at $12.13, down 8.73% over 24 hours, with technical indicators signaling a bearish trend. The stock shows strong analyst support with 9 out of 11 ratings as Buy and a consensus price target of $23.40, but fundamentals reveal challenges: negative net income margin of -26.96% and three consecutive quarterly earnings misses. Recent news highlights expansion into AI infrastructure, including a new $36 million manufacturing facility in Nevada and an AI cloud platform award in June 2026.
The outlook is mixed: bullish analyst sentiment and strategic growth in AI and mining infrastructure offer upside potential, but persistent losses, negative cash flow from operations, and high debt-to-asset ratio of 35.69% pose significant risks. Investors should weigh the company's expansion against its financial health and sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Bitdeer Technologies Group
Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.
Read more on BTDR →
